APUSApimeds Pharmaceuticals US, Inc. · NYSE American (trading under APUS.LF pending regained compliance) · $4.92 · $11.68M mkt cap
Assessed Sep 1, 2026 · Reassessment
Is the float you're seeing correct?
563.2K
Estimated float

Upper-bound reconstruction: post-split shares outstanding (1,509,118) less the 251,520 restricted Section 4(a)(2) advisory shares issued to E.F.

Confirmed · within 1%
563.2K
Reported float

Data-service feed, fetched today. The number TradingView and most screeners show.

Your screener's float is right for APUS. Trade off 563.2K shares. What it does not show you is what is about to be added to it.

Dilution risk7/10HIGH
CONFIDENCE: MEDIUM

The float your screener shows is right, at 563.2K. 4 convertible notes and 2 reverse splits can add another 2,735% of the float. This company has cut its own floor prices before.

  • Preferred stock conversion overhang. 747,702 Series A Convertible Preferred shares convert 1:20 into 14,954,040 common — 26.6x the 563,192-share tradeable float and 9.9x the 1,509,118 shares outstanding.

  • Variable-rate convertible in default (death spiral). The $10,900,000 senior secured convertible note carries a conversion price 'subject to reset and other anti-dilution adjustments, with floor provisions dependent on future market price' — the company…

  • Lock-up / Rule 144 seasoning creating new free-trading supply. 251,520 shares (16.7% of outstanding, 44.7% of the current float) were issued to E.F.

From today's float to the ceiling

shares
563.2K
Estimated float
tradeable today
+0 can sell now
563.2K
Effective supply
float plus what sells on notice
+16.35M if floors are cut and warrants exercise
16.91M
Fully diluted
ceiling

Where the shares come from

each subtotal is a rung on the ladder above

Tradeable today
563.2K
Can sell now
Warrants in the money
None of the outstanding warrants are exercisable at this price.
+0
Effective supply
563.2K
Converts only if floors are cut
Notes with no conversion price set
Sized in dollars until a price or floor is set; not counted in the ceiling. Includes unfunded commitments, which are capacity rather than outstanding debt.
$126.40M
Preferred stock, as converted
Common equivalent at the stated conversion ratio.
+14.95M
Above the current price
Warrants out of the money
Struck above the current tape; supply only if the stock rises.
+111.7K
Options and RSUs
Employee equity; vests and settles over time.
+131.0K
Other, per engine ceiling
Included in the engine's fully-diluted count but not itemised in the filings we parsed.
+1.15M
Fully diluted
16.91M

Not counted anywhere: ATM and shelf capacity. Convertible share counts use stated conversion prices.

See the full breakdown

Red flags, financing counterparties, the deal timeline, and every SEC filing — free with an account.

Sign in to continue

The facts

Price
$4.92
Market cap
$11.68M
Shares outstanding
1.51M
Reported float
563.2K
Avg volume
9.04M
Reverse splits
2 · latest 1-for-10 · Jul 24, 2026
Going concern
Yes · 0.07 quarters runway
Quarterly burn
$3.87M

Market data as of Sep 25, 2026

Key dates

  • Oct 15, 2026 · NYSE American Section 1007 initial six-month cure period expires (extendable up to six additional months to 2026-04-15); resolution here is the gating event fo…
  • Nov 11, 2026 · Approximate Rule 144 six-month seasoning of 251,520 restricted E.F. Hutton shares — could add ~45% to the tradeable float
  • Dec 8, 2026 · Senior secured convertible note ($10,900,000 redemption amount plus 18% default interest) matures
  • Dec 31, 2026 · Related-party notes ($500,100) mature
APUS Float & Dilution Analysis | ShareStructure.io